FIND® (Fragment INduced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. FIND® is used to further optimize antibodies that have previously been identified from ALLIGATOR-GOLD®. The technology allows rapid creation of a large number of functional antibody variants. From these variants, antibodies with optimized properties can be selected. The FIND® technology can be used to change virtually any property of an antibody. The improved properties may result in significant clinical benefits in terms of, for example, efficacy and potency, pharmacokinetics, safety or reduced antigenicity. Mitazalimab was developed using the FIND® technology.